• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials

byMatthew GrowdonandShaidah Deghan, MSc. MD
July 28, 2016
in Chronic Disease, Dermatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with moderate-to-severe plaque psoriasis treated with ixekizumab had significantly greater improvements in psoriasis compared to those treated with placebo at the end of both 12-week induction and 60-week follow-up periods.

2. There was an increase in the rate of infections, particularly candidal in nature, in the patients exposed to ixekizumab.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Research has identified interleukin 17A (IL-17A) as an important pathogenic agent at play in chronic plaque psoriasis, a condition that has great bearing on health-related quality of life. In the UNCOVER trials 1-3, researchers investigated the efficacy of ixekizumab, a recombinant monoclonal antibody directed at IL-17A in treating plaque psoriasis. Previously published results from UNCOVER 2&3 showed that at 12 weeks, ixekizumab was superior to placebo and twice-weekly etanercept for treatment of moderate to severe psoriasis.

In this study, the authors report efficacy and combined safety results from the multicenter, randomized, double-blind, placebo-controlled UNCOVER trials across 60 weeks of follow-up. Patients were 18 years of age or older and had moderate-to-severe plaque psoriasis. At 12 weeks of follow-up, patients had a significantly better response to ixekizumab than to placebo. At 60 weeks of follow-up, patients who received continuous treatment with ixekizumab showed a sustained improvement in psoriasis symptoms. The most common adverse events during the 12-week induction period included nasopharyngitis, URIs, injection-site reactions, and headaches. Overall, oral candidiasis occurred significantly more frequently in the ixekizumab groups in both 12- and 60-week follow-up periods.

Together, the UNCOVER trials provide compelling data that targeting IL-17A is an effective treatment strategy for moderate-to-severe plaque psoriasis, and that treatment benefits can be seen over extended follow-up. However, given the chronic need for injectable treatment, further research will have to investigate the safety profile of ixekizumab over longer periods of follow-up.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 35

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

Interleukin-23 receptor antagonist improves psoriasis symptoms

Click to read the study, published today in NEJM

Relevant Reading: Comparison of ixekizumab with etan- ercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

In-Depth [randomized controlled trial]: UNCOVER 1-3 involved over 100 worldwide sites and included 3866 adults with moderate-to-severe plaque psoriasis who were randomized to receive subcutaneous injections of placebo, etanercept, or ixekizumab in various permutations of treatment frequencies and dosages, over a 12-week induction phase followed by a total of 60-week follow-up period. The mean age of patients was 46, with a mean duration of psoriasis of 20 years; UNCOVER 2 & 3 specifically excluded patients who had received etanercept previously. Outcome measures included clinical measures of disease severity: the static Physician’s Global Assessment (sPGA) score and the Psoriasis Area and Severity Index (PASI).

In UNCOVER-1, the coprimary outcomes involved a 75% or greater reduction from baseline in PASI and a sPGA score of 0 (clear) or 1 (minimal psoriasis) at week 12. Ixekizumab was dosed either at 80mg every 2 or 4 weeks, and in both groups there was a significant improvement in the coprimary outcomes compared to placebo (p < 0.001 for all comparisons of ixekizumab with placebo). In the 2-wk dosing group, 81.8% had a sPGA score of 0 or 1 at 12 weeks, and 89.1% had a PASI-75 response. In UNCOVER-3, patients received ixekizumab for the 60-week follow-up period; at week 60, at least 73% had an sPGA score of 0 or 1, and at least 80% had a PASI 75 response. There were increased rates of infections, particularly candidal, in patients with ixekizumab exposure compared to placebo; however, an increase in major cardiovascular and cerebrovascular events was not noted.

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: psoriasis
Previous Post

Shorter course of antibiotics for community acquired pneumonia equally effective

Next Post

Empagliflozin reduces the risk of long-term renal effects in type 2 diabetes

RelatedReports

The 2 Minute Medicine Podcast Episode 15
2MM Podcast

The 2 Minute Medicine Podcast Episode 35

February 22, 2024
#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms
StudyGraphics

#VisualAbstract: Interleukin-23 receptor antagonist improves psoriasis symptoms

February 22, 2024
Severe psoriasis linked with poorly controlled blood pressure
Chronic Disease

Interleukin-23 receptor antagonist improves psoriasis symptoms

February 15, 2024
Anti-IL-17A therapy linked to sustained improvement in plaque psoriasis: The UNCOVER trials
Chronic Disease

Spesolimab may improve quality of life in patients with generalized pustular psoriasis flares

November 14, 2023
Next Post
Intrapartum serum prolactin may predict risk of postpartum diabetes

Empagliflozin reduces the risk of long-term renal effects in type 2 diabetes

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Liraglutide associated with lower incidence of death from CV causes in type 2 diabetics

Image-guided percutaneous drainage of pericardial effusions is safe and effective

Point-of-care hemostatic test during TAVR procedure may help predict negative outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.